MannKind reported $321.63M in Ordinary Share Capital for its fiscal quarter ending in September of 2026.





Ordinary Share Capital Change Date
Adma Biologics USD 225.36M 6.93M Jun/2026
BioCryst Pharmaceuticals USD 255.26M 42.2M Jun/2026
Eli Lilly USD 943.5M 3.33M Mar/2026
Halozyme Therapeutics USD 113.94M 106K Sep/2026
Insmed USD 218.28M 1.76M Jun/2026
Karyopharm Therapeutics USD 22.54M 4.23M Mar/2026
MacroGenics USD 63.65M 86K Jun/2026
MannKind USD 321.63M 11.72M Sep/2026
Merck USD 2.47B 1.05M Jun/2026
Minerva Neurosciences USD 1000 0 Sep/2024
Novavax USD 162.58M 106K Dec/2025
Novo Nordisk DKK 4.43B 13.25M Jun/2026
Pfizer USD 5.7B 0 Jun/2026
Sanofi EUR 1.2B 0 Sep/2026
Xencor USD 74.33M 265K Jun/2026